Ahmed Abdullah M Lahiq

Dr. Ahmed Abdullah M Lahiq

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2023 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
USUswa Shafique
Uswa Shafique
FUFakhar Ud-din
Fakhar Ud-din
SSSaba Sohail
Saba Sohail
SBSibgha Batool
Sibgha Batool
AAALI H. ALAMRI
ALI H. ALAMRI
HAHanan Mohammed Alharbi
Hanan Mohammed Alharbi

28 June 2024 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
MRMuneeba Rafique
Muneeba Rafique
ZAZakir Ali
Zakir Ali
SSSaba Sohail
Saba Sohail
FZFatima Zahid
Fatima Zahid
MKMuhammad Ibrar Khan
Muhammad Ibrar Khan
ALAhmed Abdullah M Lahiq
Ahmed Abdullah M Lahiq

3 December 2023 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
MMMaimoona Malik
Maimoona Malik
ZAZakir Ali
Zakir Ali
SKSalman Khan
Salman Khan
AZAlam Zeb
Alam Zeb
FUFakhar Ud-din
Fakhar Ud-din
ALAhmed Abdullah M Lahiq
Ahmed Abdullah M Lahiq

17 May 2024 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
MJMuhammad Jawad
Muhammad Jawad
USUswa Shafique
Uswa Shafique
FUFakhar Ud-din
Fakhar Ud-din
ABAiny Butt
Ainy Butt
SKSalman Khan
Salman Khan
KAKhulod S. Almerai
Khulod S. Almerai

Verified
Journal Article
Open access
PDF file
MOMohamed A. A. Orabi
Mohamed A. A. Orabi
ALAhmed Abdullah M Lahiq
Ahmed Abdullah M Lahiq
AAAhmed Abdullah Al Awadh
Ahmed Abdullah Al Awadh
MAMohammed Merae Alshahrani
Mohammed Merae Alshahrani
Basel A Abdel-WahabBasel A Abdel-Wahab
Basel A Abdel-Wahab
EAEl-Shaymaa Abdel-Sattar
El-Shaymaa Abdel-Sattar
With more than 12 million cases worldwide, leishmaniasis is one of the top 10 neglected tropical diseases. According to the WHO, there are approximately 2 million new cases each year in foci in around 90 countries, of which 1.5 million are cutaneous leishmaniasis (CL). Cutaneous leishmaniasis (CL) is a complex cutaneous condition that is caused by a variety of Leishmania species, including L. (Leishmania) major, L. (L) tropica, L. (L) aethiopica, L. (L) mexicana, L. (Viannia) braziliensis, and L. (L) amazonensis. The disease imposes a significant burden on those who are affected since it typically results in disfiguring scars and extreme social stigma. There are no vaccines or preventive treatments available, and chemotherapeutic medications, including antimonials, amphotericin B, miltefosine, paromomycin, pentamidine, and antifungal medications, have a high price tag, a significant risk of developing drug resistance, and a variety of systemic toxicities. To work around these limitations, researchers are continuously looking for brand-new medications and other forms of therapy. To avoid toxicity with systemic medication use, high cure rates have been observed using local therapy techniques such as cryotherapy, photodynamic therapy, and thermotherapy, in addition to some forms of traditional therapies, including leech and cauterization therapies. These CL therapeutic strategies are emphasized and assessed in this review to help with the process of locating the appropriate species-specific medicines with fewer side effects, lower costs, and elevated cure rates.

9 December 2023 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
ASAiman Saleem
Aiman Saleem
FUFakhar Ud-din
Fakhar Ud-din
ZAZakir Ali
Zakir Ali
FZFatima Zahid
Fatima Zahid
AAALI H. ALAMRI
ALI H. ALAMRI
HAHanan Mohammed Alharbi
Hanan Mohammed Alharbi